Competitive Outlook of Cancer Drug Development

Summary

This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three
different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). The report is written for you to understand and assess the impact of competitor entry and corresponding
changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

Assisting you to make informed decisions in selecting lung cancer sub-indications that are known to be appropriate for your drug's properties

Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is
commercialized.

Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents
4.1 List of Figures
4.2 List of Tables

5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Lung Cancer Drug Targets
6.2.1 Carboxy-lyase Activity Targets
6.2.2 Catalytic ActivityTargets
6.2.3 Cell Adhesion Molecule Activity Targets
6.2.4 Chaperone ActivityTargets
6.2.5 Chemokine Activity Targets
6.2.6 Complement Activity Targets
6.2.7 Cysteine-Type Peptidase Activity Targets
6.2.8 Cytokine Activity Targets
6.2.9 DNA Binding Targets
6.2.10 DNA Repair Protein Targets
6.2.11 DNA Topoisomerase Activity Targets
6.2.12 DNA-Directed DNA Polymerase Activity Targets
6.2.13 DNA-methyltransferase Activity Targets
6.2.14 Extracellular Ligand-Gated Ion Channel Activity Targets
6.2.15 Extracellular Matrix Structural Constituent Targets
6.2.16 G-protein Coupled Receptor Activity Targets
6.2.17 Glutathione Transferase Activity Targets
6.2.18 Growth Factor Activity Targets
6.2.19 GTPase Activity Targets
6.2.20 Hormone activity Targets
6.2.21 Hydrolase Activity Targets
6.2.22 Ion channel Activity Targets
6.2.23 Kinase Activity Targets
6.2.24 Kinase regulator activity Targets
6.2.25 Ligase Activity Targets
6.2.26 Lipase Activity Targets
6.2.27 Lipid Kinase Activity Targets
6.2.28 Metallopeptidase Activity Targets
6.2.29 Molecular Function Unknown Targets
6.2.30 Motor Activity Targets
6.2.31 Oxidoreductase Activity Targets
6.2.32 Peptidase Activity Targets
6.2.33 Peroxidase Activity Targets
6.2.34 Phosphoric Diester Hydrolase Activity Targets
6.2.35 Protein binding Targets
6.2.36 Protein Serine/Threonine Kinase Activity Targets
6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets
6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets
6.2.39 Protein-Tyrosine Kinase Activity Targets
6.2.40 Receptor Activity Targets
6.2.41 Receptor binding Targets
6.2.42 Receptor Signaling Complex Scaffold Activity Targets
6.2.43 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
6.2.44 RNA Binding Targets
6.2.45 RNA-Directed DNA Polymerase Activity Targets
6.2.46 Serine-Type Peptidase Activity Targets
6.2.47 Structural Constituent of Cytoskeleton Targets
6.2.48 Transcription Factor Activity Targets
6.2.49 Transcription Regulator Activity Targets
6.2.50 Transcription Regulator Activity Targets
6.2.51 Transferase Activity Targets
6.2.52 Transmembrane Receptor Activity Targets
6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.54 Transporter Activity Targets
6.2.55 Ubiquitin-Specific Protease Activity Targets
6.2.56 Other Targets
6.3 The Cancer Genome Project and Lung Cancer Targets
6.3.1 Lung Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Structure-based Drug Design in Lung Cancer is Stimulated by Available Structure Data on Biological Targets
6.5 Target-Target Interactions among Identified Lung Cancer Targets
6.6 The Drug-Target Interactome
6.7 Protein Expression Levels of Identified Drug Targets of Lung Cancer Drugs
6.8 Pathway Analysis of Lung Cancer Drug Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline?
7.1 Terminated Drug Target Profiles in Lung Cancer
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lung Cancer Pipeline
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lung Cancer Pipeline
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer
Pipeline
7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline
7.7 Development Profiles of All Lung Cancer Drug Target Profiles

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound
8.1 Small Molecules
8.1.1 Background
8.1.2 Targets in Lung Cancer
8.2 Peptide/Protein Drugs
8.2.1 Background
8.2.2 Targets in Lung Cancer
8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Targets in Lung Cancer
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Targets in Lung Cancer
8.5 Gene Therapy
8.5.1 Background
8.5.2 Targets in Lung Cancer
8.6 Drug Delivery and Nanotechnology
8.6.1 Background
8.6.2 Targets in Lung Cancer
8.7 The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer
8.8 Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets

9 Selecting a Sub-Indication of Lung Cancer for Drug Development
9.1 Lung Cancer (general)
9.1.1 Players and their Compared Pipeline
9.1.2 Where is the Real Competition?
9.1.3 How Successful are They in Their Targeting Strategy?
9.2 Non-Small Cell Lung Cancer
9.2.1 Players and their Compared Pipeline
9.2.2 Where is the Real Competition?
9.2.3 How Successful are They in Their Targeting Strategy?
9.3 Small Cell Lung Cancer
9.3.1 Players and their Compared Pipeline
9.3.2 Where is the Real Competition?
9.3.3 How Successful are They in Their Targeting Strategy?

10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator463
10.1 Abbott
10.2 Abraxis BioScience
10.3 Active Biotech
10.4 Adherex
10.5 Advantagene
10.6 AEgera
10.7 Aeterna Zentaris
10.8 Agennix
10.9 Aida Pharmaceuticals
10.10 Alchemia
10.11 Alethia Biotherapeutics
10.12 Allos Therapeutics
10.13 Amgen
10.14 Antisense Pharma
10.15 Antisoma
10.16 Anza Therapeutics
10.17 ApopLogic Pharmaceuticals
10.18 Archer Biosciences
10.19 Ariad
10.20 ArQule
10.21 Array BioPharma
10.22 Ascenta Therapeutics
10.23 Astellas
10.24 AstraZeneca
10.25 Bayer
10.26 Biogen Idec
10.27 Biokine Therapeutics
10.28 BioNumerik
10.29 Boehringer Ingelheim
10.30 Bristol-Myers Squibb
10.31 BTG
10.32 CanBas
10.33 Celator Pharmaceuticals
10.34 Cell Genesys
10.35 Cell Therapeutics
10.36 Celtic Pharma
10.37 Center of Molecular Immunology
10.38 Cephalon
10.39 CG Therapeutics
10.40 Chemokine Therapeutics
10.41 Chong Kun Dang
10.42 Clavis Pharma
10.43 CLL Pharma
10.44 Critical Outcome Technologies
10.45 Cyclacel
10.46 CytImmune Sciences
10.47 Cytokinetics
10.48 Dabur Pharma
10.49 Daiichi Sankyo
10.50 Dainippon Sumitomo Pharma
10.51 Dara Biosciences
10.52 Dendreon
10.53 Dong-A
10.54 Eisai
10.55 Eli Lilly
10.56 Endocyte
10.57 EntreMed
10.58 EpiCept
10.59 Exelixis
10.60 Galapagos
10.61 Gemin X Pharmaceuticals
10.62 Genentech
10.63 Genmab
10.64 Genta
10.65 GenVec
10.66 Genzyme
10.67 Geron
10.68 GlaxoSmithKline
10.69 GlobeImmune
10.70 GlycoGenesys
10.71 Hana Biosciences
10.72 Hoffmann-La Roche
10.73 Human Genome Sciences
10.74 Idera Pharmaceuticals
10.75 ImClone Systems
10.76 ImmunoCellular Therapeutics
10.77 Immunocore
10.78 ImmunoGen
10.79 Immunomedics
10.80 Incyte Corporation
10.81 Infinity Pharmaceuticals
10.82 Innovive
10.83 Inovio
10.84 Introgen Therapeutics
10.85 Ipsen
10.86 Isis Pharmaceuticals
10.87 Jennerex Biotherapeutics
10.88 Johnson & Johnson
10.89 Kiadis
10.90 Kyowa Hakko Kirin
10.91 Lorus Therapeutics
10.92 MacroGenics
10.93 Medarex
10.94 MediGene
10.95 Medisyn Technologies
10.96 Menarini
10.97 Merck KGaA
10.98 MethylGene
10.99 Micromet
10.100 Mirna Therapeutics
10.101 MolMed
10.102 Mologen
10.103 Nektar Therapeutics
10.104 NeoPharm
10.105 Nerviano Medical Sciences
10.106 Novacea
10.107 Novartis
10.108 OncoGenex Pharmaceuticals
10.109 Oncothyreon
10.110 OSI Pharmaceuticals
10.111 OXiGENE
10.112 PanaGin
10.113 PBL Therapeutics
10.114 PDL BioPharma
10.115 Pfizer
10.116 Pharmacyclics
10.117 PharmaGap
10.118 PharmaMar
10.119 Pharmexa
10.120 Pierre Fabre
10.121 Pro-Pharmaceuticals
10.122 Progen
10.123 Protox Therapeutics
10.124 Receptor BioLogix
10.125 Regulon
10.126 RESprotect
10.127 Samyang
10.128 Sanofi-Aventis
10.129 Sareum
10.130 Schering-Plough
10.131 Seattle Genetics
10.132 ShimodaAtlantic Oncology
10.133 Shire
10.134 Sigma-Tau
10.135 Simcere Pharmaceuticals
10.136 SRI International
10.137 SuperGen
10.138 Supratek Pharma
10.139 Switch Pharma
10.140 Taiho
10.141 Takeda
10.142 Taxolog
10.143 Tekmira Pharmaceuticals
10.144 Telik
10.145 Thallion Pharmaceuticals
10.146 Therion Biologics
10.147 Titan Pharmaceuticals
10.148 Tracon Pharmaceuticals
10.149 Tragara Pharmaceuticals
10.150 Transgene
10.151 Trion Pharma
10.152 Twinstrand Therapeutics
10.153 UCB
10.154 Valeant
10.155 Vaxon Biotech
10.156 Vertex Pharmaceuticals
10.157 Vion Pharmaceuticals
10.158 ViRexx
10.159 Voyager Pharmaceutical
10.160 Wilex
10.161 Wyeth
10.162 Xerion
10.163 Xoma
10.164 Yakult Honsha
10.165 YM BioSciences
10.166 Zivena
10.167 Non-industrial Organizations
11 Disclaimer
12 Drug Index
13 Company Index

List of Figures

Figure 1: Overall Breakdown of the Included Lung Cancer Therapeutic Pipeline by Sub-Indication and Stage of Development
Figure 2: Visualization of Target-Target Interactions Among Lung Cancer Drug Targets
Figure 3: The Drug-Protein Interactome of Lung Cancer Drugs -Clusters I
Figure 4: The Drug-Protein Interactome of Lung Cancer Drugs - Clusters II
Figure 5: Head-to-Head Targeting Interactome of Lung Cancer Drugs
Figure 6: Distribution of Compound Types among Lung Cancer Drugs
Figure 7: Primary Sub-cellular Localization of Drug Targets
Figure 8: Breakdown of the Lung Cancer (general) Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 9: Compound Strategy Breakdown of the Lung Cancer (general) Pipeline
Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 11: Compound Strategy Breakdown of the Non-Small Cell Lung Cancer Pipeline
Figure 12: Breakdown of the Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 13: Compound Strategy Breakdown of the Small Cell Lung Cancer Pipeline

List of Tables

Table 1: Competitive Pressure Force Among Lung Cancer Drugs
Table 2: Overview of Drug Target Profile Themes
Table 3: Terminally Ceased Therapeutic Lung Cancer Targets
Table 4: Drug Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 5: Identity of Lung Cancer Drug Targets with Available Biological Structures
Table 6: Number of Target-Target Interactions among Lung Cancer Drug Targets
Table 7: Drug-Protein Interactome Clusters
Table 8: Lung Cancer Drug Targets with Available Protein Expression Profiles
Table 9: Expression Levels of Identified Drug Targets in Lung Cancer Tissue
Table 10: Pathway Summary
Table 11: Drug Targets without any Identified Assigned Pathways
Table 12: Pathway Profile According to BioCarta of Lung Cancer Drug Targets
Table 13: Pathway Profile According to KEGG of Lung Cancer Drug Targets
Table 14: Pathway Profile According to NetPath of Lung Cancer Drug Targets
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness
Table 16: Top Competitive Lung Cancer Target Profiles
Table 17: Terminated Drug Target Strategies in Lung Cancer
Table 18 New and Unique Lung Cancer Target Strategies in Pre-Registration to Marketed
Table 19: New and Unique Lung Cancer Target Strategies in Phase III Clinical Development
Table 20: New and Unique Lung Cancer Target Strategies in Phase II Clinical Development
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs
Table 22 New and Unique Lung Cancer Target Strategies in Phase I Clinical Development
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs
Table 24: New and Unique Lung Cancer Target Strategies in Preclinical Development
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs
Table 26: The Progression, Maturity and Competitive Comparison of Lung Cancer Drug Target Profiles in Development
Table 27: Overview of Compound Strategy Competition in Lung Cancer
Table 28:Overview of the Competitive Landscape of Small Molecular Drugs in Lung Cancer
Table 29: Head-to-Head Target Competition Between Small Molecule Drugs for the Treatment of Lung Cancer
Table 30: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lung Cancer
Table 31: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Lung Cancer Drugs in Development
Table 32: Overview of the Competitive Landscape of Peptide Based Drugs in Lung Cancer
Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Lung Cancer Drug in Development
Table 34:Overview of the Competitive Landscape of Protein Based Drugs in Lung Cancer
Table 35: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lung Cancer
Table 36: The Progression, Maturity and Competitive Comparison of Protein Based Lung Cancer Drug Target Profiles in Development
Table 37:Overview of the Competitive Landscape of Antibody Drugs in Lung Cancer
Table 38: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lung Cancer
Table 39: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Lung Cancer Drugs in Development
Table 40:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lung Cancer
Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Lung Cancer Drugs in Development
Table 42: Vectors in Gene Therapy
Table 43:Overview of the Competitive Landscape of Gene Therapy Drugs in Lung Cancer
Table 44: The Competition Through Close Mechanistic Approximation Between Gene Therapy Drugs in Lung Cancer
Table 45: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Lung Cancer Drugs in Development
Table 46:Overview of the Competitive Landscape of Reformulated Drugs in Lung Cancer
Table 47: The Competition Through Close Mechanistic Approximation Between Reformulated Drugs in Lung Cancer
Table 48: The Progression, Maturity and Competitive Comparison of Target Profiles of Reformulated Lung
Cancer Drugs in Development
Table 49: The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer
Table 50: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets
Table 51: Competitive Summary of Lung Cancer Drugs by Sub-Indication
Table 52: Players in the Field of Lung Cancer (general) Drug Development and their Compared Pipeline
Table 53: The Competition Through Close Mechanistic Approximation Between Lung Cancer (general) Drugs
Table 54: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lung Cancer
(general) Drug Development
Table 55: Players in the Field of Non-Small Cell Lung Cancer Drug Development and their Compared Pipeline
Table 56: The Competition Through Close Mechanistic Approximation Between Non-Small Cell Lung Cancer
Drugs
Table 57: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Small Cell Lung
Cancer Drug Development
Table 58: Players in the Field of Small Cell Lung Cancer Drug Development and their Compared Pipeline
Table 59: The Competition Through Close Mechanistic Approximation Between Small Cell Lung Cancer Drugs
Table 60: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Small Cell Lung
Cancer Drug Development
Table 61: Abbott's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 62: Abraxis BioScience's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 63: Active Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 64: Adherex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 65: Advantagene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 66: AEgera's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 67: Aeterna Zentaris' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 68: Agennix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 69: Aida Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 70: Alchemia's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 71: Alethia Biotherapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 72: Allos Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 73: Amgen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 74: Antisense Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 75: Antisoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 76: Anza Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 77: ApopLogic Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 78: Archer Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 79: Ariad's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 80: ArQule's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 81: Array BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 82: Ascenta Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 83: Astellas' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 84: AstraZeneca's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 85: Bayer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 86: Biogen Idec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 87: Biokine Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 88: BioNumerik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 89: Boehringer Ingelheim's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 90: Bristol-Myers Squibb's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 91: BTG's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 92: CanBas' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 93: Celator Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 94: Cell Genesys' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 95: Cell Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 96: Celtic Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 97: Center of Molecular Immunology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 98: Cephalon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 99: CG Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 100: Chemokine Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 101: Chong Kun Dang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 102: Clavis Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 103: CLL Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 104: Critical Outcome Technologies' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 105: Cyclacel's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 106: CytImmune Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 107: Cytokinetics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 108: Dabur Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 109: Daiichi Sankyo's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 110: Dainippon Sumitomo Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 111: Dara Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 112: Dendreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 113: Dong-A's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 114: Eisai's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 115: Eli Lilly's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 116: Endocyte's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 117: EntreMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 118: EpiCept's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 119: Exelixis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 120: Galapagos' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 121: Gemin X Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 122: Genentech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 123: Genmab's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 124: Genta's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 125: GenVec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 126: Genzyme's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 127: Geron's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 128: GlaxoSmithKline's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 129: GlobeImmune's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 130: GlycoGenesys' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 131: Hana Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 132: Hoffmann-La Roche's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 133: Human Genome Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 134: Idera Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 135: ImClone Systems' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 136: ImmunoCellular Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 137: Immunocore's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 138: ImmunoGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 139: Immunomedics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 140: Incyte Corporation's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 141: Infinity Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 142: Innovive's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 143: Inovio's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 144: Introgen Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 145: Ipsen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 146: Isis Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 147: Jennerex Biotherapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 148: Johnson & Johnson's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 149: Kiadis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 150: Kyowa Hakko Kirin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 151: Lorus Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 152: MacroGenics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 153: Medarex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 154: MediGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 155: Medisyn Technologies' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 156: Menarini's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 157: Merck KGaA's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 158: MethylGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 159: Micromet's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 160: Mirna Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 161: MolMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 162: Mologen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 163: Nektar Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 164: NeoPharm's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 165: Nerviano Medical Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 166: Novacea's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 167: Novartis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 168: OncoGenex Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 169: Oncothyreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 170: OSI Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 171: OXiGENE's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 172: PanaGin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 173: PBL Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 174: PDL BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 175: Pfizer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 176: Pharmacyclics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 177: PharmaGap's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 178: PharmaMar's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 179: Pharmexa's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 180: Pierre Fabre's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 181: Pro-Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 182: Progen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 183: Protox Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 184: Receptor BioLogix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 185: Regulon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 186: RESprotect's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 187: Samyang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 188: Sanofi-Aventis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 189: Sareum's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 190: Schering-Plough's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 191: Seattle Genetics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 192: ShimodaAtlantic Oncology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 193: Shire's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 194: Sigma-Tau's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 195: Simcere Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 196: SRI International's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 197: SuperGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 198: Supratek Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 199: Switch Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 200: Taiho's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 201: Takeda's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 202: Taxolog's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 203: Tekmira Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 204: Telik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 205: Thallion Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 206: Therion Biologics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 207: Titan Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 208: Tracon Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 209: Tragara Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 210: Transgene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 211: Trion Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 212: Twinstrand Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 213: UCB's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 214: Valeant's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 215: Vaxon Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 216: Vertex Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 217: Vion Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 218: ViRexx's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 219: Voyager Pharmaceutical's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 220: Wilex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 221: Wyeth's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 222: Xerion's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 223: Xoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 224: Yakult Honsha's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 225: YM BioSciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 226: Zivena's Included Lung Cancer Pipeline Composition and Competitive Fall-Out
Table 227: Non-industrial source's Included Lung Cancer Pipeline Composition and Competitive Fall-Out